ArticleInternational journal of retina and vitreous2026
Surgical prognosis in epiretinal membrane: 12-month outcomes after membrane peeling in a 5-year cohort with OCT biomarkers.
Article in International journal of retina and vitreous, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo determine the functional and anatomical outcomes at 12 months after pars plana vitrectomy (PPV) for epiretinal membrane (ERM) and the independent prognostic value of preoperative biomarkers in optical coherence tomography (OCT).
methodsFive-year analytical study of 340 eyes with ERM in stages (Govetto G2-4). Best-corrected visual acuity (BCVA) logMAR and OCT were evaluated at baseline, 1, 3, 6, and 12 months. The primary objective was to determine the change in BCVA at 12 months (ΔlogMAR 12 m - baseline). Univariate tests, ANCOVA, longitudinal mixed linear models, and logistic regression were applied for gain ≥ 0.2 logMAR. The models were adjusted for baseline VA, age, sex, aetiology, surgical technique, and analysis of biomarkers in OCT.
resultsBaseline VA was 0.54 ± 0.44 logMAR (approximate Snellen equivalent: 20/70); distribution according to G2 (n = 166), G3 (n = 146), G4 (n = 28). VA improved significantly at 12 months (Wilcoxon p < 0.001), equivalent to 11-12 ETDRS letters. Secondary ERMs showed greater unadjusted gain than idiopathic ones, but aetiology was not an independent predictor after adjustment. The surgical technique was not independently associated with VA at 12 months (β=+0.031 logMAR; 95% CI; p = 0.408) or with responder status (OR 1.18; 95% CI; p = 0.625). By severity, advanced stages had worse baseline visual acuity (VA) and greater absolute gains (Kruskal-Wallis H = 7.61; p = 0.0223), although with lower final VA compared to lesser stages. Baseline VA was the dominant predictor in all models (β=-0.766; 95% CI; p < 0.001). Among preoperative biomarkers, COST line disruption independently increased the probability of response (OR = 2.08; 95% CI; p = 0.013). DRIL, EZ disruption, and central bouquet alterations did not reach significance after adjustment. Mixed models confirmed early improvement, maintained up to 12 months. Kaplan-Meier showed faster time to response in advanced stages.
conclusionsPPV for ERM achieves significant improvement at 12 months. Baseline VA is the main determinant of prognosis. According to Govetto's classification, the greatest gain occurs in advanced stages, but with lower final VA. The COST line emerges as the only preoperative biomarker with independent prognostic value for achieving ≥ 0.2 logMAR; the others provide limited utility when baseline VA is considered.
trial registrationNot applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.